Compare Canopy Growth Corp (CGC) vs JPMorgan Chase & Co (JPM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Canopy Growth Corp vs JPMorgan Chase & Co — how do they compare? Canopy Growth Corp trades at $1.03 (market cap $421.10M), while JPMorgan Chase & Co trades at $365.34 (market cap $962.37B). The key difference: JPMorgan Chase & Co is far larger — about 2285.4× Canopy Growth Corp's market cap, and JPMorgan Chase & Co pays a 1.66% dividend while Canopy Growth Corp pays none. Which is the better fit depends on your goals.
| CGC | JPM | |
|---|---|---|
Market Cap | $421.10M | $962.37B |
Sector | Health | Financials |
52-Week High | $1.92 | $362.04 |
52-Week Low | $0.86 | $282.84 |
Enterprise Value | $378.55M | — |
Volume | — | 10,479,943 |
Dividend Yield | — | 1.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Canopy Growth (CGC) trades at $1.025, up 7.66% with bullish technical signals. The company shows improving fundamentals with Q1 2027 revenue growth of 13% and narrowing losses. Recent acquisitions and cost-cutting initiatives support expansion in medical and European cannabis markets. The stock trades below book value (P/B 0.86) while maintaining a P/S ratio of 1.71.
CGC presents a high-risk turnaround opportunity with improving balance sheet metrics and positive revenue momentum. However, persistent negative earnings and cash flow challenges require careful monitoring. Analyst sentiment remains divided with 33% buy ratings, reflecting the speculative nature of cannabis sector investments amid ongoing regulatory uncertainty.
JPMorgan Chase & Co. (JPM) trades at $362.04, up 0.63% daily, with a bullish technical outlook and strong earnings beats in recent quarters. The stock shows robust fundamentals, including a P/E of 15.51 and ROE of 18.43%, supported by revenue growth to $181.85B in 2025. Recent news highlights CEO Jamie Dimon's economic warnings and positive analyst sentiment ahead of Q1 2026 earnings.
Outlook is positive with a consensus price target of $374.18, offering ~3.4% upside, but risks include geopolitical tensions, cybersecurity threats, and volatile cash flows. Investors should weigh strong profitability against macroeconomic headwinds for balanced exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Canopy Growth Corp
Canopy Growth, headquartered in Smiths Falls, Canada, cultivates and sells medicinal and recreational cannabis, and hemp, through a portfolio of brands that include Tweed, Spectrum Therapeutics, and CraftGrow. Although it primarily operates in Canada, Canopy has distribution and production licenses in more than a dozen countries to drive expansion in global medical cannabis and also holds an option to acquire Acreage Holdings upon U.S. federal cannabis legalization.
Read more on CGC →About JPMorgan Chase & Co
JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.
Read more on JPM →
